CyberKnife has treated thousands of brain lesions, with individual studies and centers reporting results for hundreds of patients (338 patients in one study) and specific instances of treating over 60 metastatic lesions in a single patient.
It is highly effective, with studies showing a 90% local control rate for brain metastases.
Key Treatment Statistics and Findings:
Case Volume: A study mentioned 338 patients with brain tumors were treated over 7 years.
Another center (Asan Medical Center) has performed 425 CyberKnife surgeries for metastatic brain tumors and 639 for benign, for a total of 1,064.
Lesion Count: Single studies have tracked 109, 148, and 233 metastatic brain lesions.
High-Volume Capacity: A case study noted the successful treatment of 62 metastatic brain lesions resulting from breast cancer in a single patient.
Effectiveness: Local control rates for brain metastases are often reported to be between 83% and 92%.
Types of Lesions: Used for both benign tumors (meningioma, acoustic neuroma) and malignant metastases, (with a 95% success rate in stopping growth)
Common Primary Cancers Treated:
Lung (40.2%)
Kidney (22.7%)
Melanoma (15.5%)
Breast (1)
CyberKnife is considered a, if not “the,” method of choice for patients with 1-to-4 metastases, but it is also used for 5 or more, particularly for radio-resistant tumors.
While there is no single global registry documenting every individual brain lesion ever treated by CyberKnife, clinical data and institutional reports demonstrate its capacity to handle both large volumes of patients and complex cases involving many lesions in a single individual:
A single woman with breast cancer was successfully treated for 62 metastatic brain lesions using CyberKnife radio-surgery.
Another documented case involved the resolution of 24 brain metastases from lung cancer within three months.
Institutional Reach: Since its FDA approval in 2001, CyberKnife has been used to treat thousands of patients for brain and spinal tumors across various specialized centers.
For example, the CyberKnife Center of Miami alone has treated over 4,000 patients for various conditions.
A Deeper Dive:
Clinical Studies: Large-scale research highlights its widespread application:
One study monitored 333 patients specifically for tumor metastases to the brain.
Another focused on 133 patients with brain metastases suffering from symptoms like headaches and seizures.
A multi-center study analyzed 144 brainstem metastases (an extremely challenging location) in 136 patients.
Versatility in Lesion Types: It is used for a broad range of indications, including meningiomas (with a 95% success rate in stopping growth), acoustic neuromas, arteriovenous malformations (AVMs), and trigeminal neuralgia.
To find out if CyberKnife treatment is an option for you, call one of the most experienced teams worldwide at the CyberKnife Center of Miami.
They will tell you straight up if they can help you, or if there is a better cancer treatment option for you.
Call 305-279-2900 and go to our website now for more information www.cyberknifemiami.com
Here is a video demonstration of brain tumor treatment with CyberKnife on our YouTube channel.
https://youtu.be/fKS4pWT6Y9Y
Follow us on social media to see the newest information on CyberKnife treatment for all types of cancer and nerve disorders.